131 related articles for article (PubMed ID: 25989801)
1. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.
Park JO; Oh DY; Hsu C; Chen JS; Chen LT; Orlando M; Kim JS; Lim HY
Cancer Res Treat; 2015 Jul; 47(3):343-61. PubMed ID: 25989801
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer.
Lee J; Hong TH; Lee IS; You YK; Lee MA
Cancer Res Treat; 2015 Apr; 47(2):259-65. PubMed ID: 25648099
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Weigt J; Malfertheiner P
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):395-7. PubMed ID: 20678012
[TBL] [Abstract][Full Text] [Related]
4. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study.
Lee SH; Lee HS; Lee SH; Woo SM; Kim DU; Bang S
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517311
[TBL] [Abstract][Full Text] [Related]
7. Long term responders to palliative chemotherapy for advanced biliary tract cancer.
Doherty MK; McNamara MG; Aneja P; McInerney E; Moignard S; Horgan AM; Jiang H; Panzarella T; Jang R; Dhani N; Hedley D; Knox JJ
J Gastrointest Oncol; 2017 Apr; 8(2):352-360. PubMed ID: 28480074
[TBL] [Abstract][Full Text] [Related]
8. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity.
Luo Y; Li JL; Yang L; Zhang W
Thorac Cancer; 2016 Mar; 7(2):167-72. PubMed ID: 27042218
[TBL] [Abstract][Full Text] [Related]
11. A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.
Nishimura M
World J Hepatol; 2010 May; 2(5):192-7. PubMed ID: 21160995
[TBL] [Abstract][Full Text] [Related]
12. Biliary tract cancer: current challenges and future prospects.
Ghidini M; Pizzo C; Botticelli A; Hahne JC; Passalacqua R; Tomasello G; Petrelli F
Cancer Manag Res; 2019; 11():379-388. PubMed ID: 30643463
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for biliary tract cancer.
Furuse J; Okusaka T
Cancers (Basel); 2011 May; 3(2):2243-54. PubMed ID: 24212807
[TBL] [Abstract][Full Text] [Related]
14. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer.
Kim H; Kim R; Kim HR; Jo H; Kim H; Ha SY; Park JO; Park YS; Kim ST
Front Oncol; 2022; 12():834104. PubMed ID: 35252005
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Yan X; Zou H; Lai Y; Ung COL; Hu H
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612035
[TBL] [Abstract][Full Text] [Related]
16. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.
Ulahannan SV; Rahma OE; Duffy AG; Makarova-Rusher OV; Kurtoglu M; Liewehr DJ; Steinberg SM; Greten TF
Hepat Oncol; 2015 Jan; 2(1):39-50. PubMed ID: 25685318
[TBL] [Abstract][Full Text] [Related]
17. Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases.
Alshari OM; Dawaymeh TA; Tashtush NA; Aleshawi AJ; Al Manasra ARA; Obeidat KA
Onco Targets Ther; 2019; 12():5293-5298. PubMed ID: 31308699
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy.
Wu CE; Huang WK; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201707
[TBL] [Abstract][Full Text] [Related]
19. Orphan drugs in different countries and development of new drugs to treat biliary tract cancer.
Cheng H; Zhou D; Wang S; Ding J; Ma F
Intractable Rare Dis Res; 2021 May; 10(2):146-147. PubMed ID: 33996363
[TBL] [Abstract][Full Text] [Related]
20. Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review.
Xue R; Li R; Wang J; Tong W; Hao J
J Clin Transl Hepatol; 2021 Aug; 9(4):559-567. PubMed ID: 34447686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
